COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease

Heart Failure Clinical Trial

— COLT-HF  

Official title:

COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05873881
• Other study ID #: PHRI.COLT-HF
• Status: Recruiting
• Phase: Phase 3
• Start date: January 29, 2024
• Est. completion date: June 2027

Study information

• Verified date: February 2024
• Source: Hamilton Health Sciences Corporation
• Contact: Philip G Joseph, M.D.
• Phone: 905-521-2100
• Email: philip.joseph[@]phri.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this 2x2 factorial clinical trial is to test the efficacy of i) colchicine, and ii) thiamine in heart failure (HF) secondary to ischemic heart disease. The main questions it aims to answer are:

• Does colchicine reduce the risk of cardiovascular (CV) death, a HF event, or an ischemic CV event

• Does thiamine reduce the risk of cardiovascular (CV) death, or a HF event

Participants will undergo the following procedures:

• Run-in: All participants will receive colchicine 0.5 mg daily to assess drug tolerance over a 3-4 week period.

• Randomization: If colchicine is tolerated during run-in, eligible participants will be randomized in a 2x2 factorial design to receive i) colchicine 0.5mg daily or placebo, and ii) thiamine 300mg daily or no thiamine.

• Follow-up: Clinical outcomes, side effects, adverse events, and drug adherence will be captured during follow-up

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2500
• Est. completion date: June 2027
• Est. primary completion date: June 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 45 Years and older

Eligibility

Inclusion Criteria:

1. Age >/= 45 years

2. Documented ischemic HF as the etiology of HF, which includes:

1. a prior history of CAD (defined as a history of myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, or non-invasive or invasive cardiac testing consistent with a diagnosis of CAD), and

2. determination of CAD to be the cause primary cause of HF based on local investigator assessment

3. New York Heart Association (NYHA) class II-IV symptoms

4. Documented LVEF </= 45% within 1 year prior to enrollment

5. Optimization of HF treatment based on local practice.

6. Ambulatory HF patients or stable hospitalized patients with HF will both be eligible for enrollment in the trial. For hospitalized patients, enrollment will require i) evidence of clinical stability from HF defined as no use of an inotropic agent or intravenous diuretic agent in the prior 24, and ii) expected discharge from hospital in the next 72 hours.

Exclusion Criteria:

1. Female who is pregnant, breast-feeding, or of childbearing potential and not using an effective form of birth control*

2. Regular or required use colchicine or thiamine for other clinical indications.**

3. History of allergic reaction to colchicine or to thiamine; or current or planned use of cyclosporine, verapamil, diltiazem, azole antifungal, macrolide antibiotic (except azithromycin), or HIV protease inhibitor

4. Use of a ventricular assist device or prior heart transplant

5. Coronary revascularization (coronary artery bypass graft surgery or percutaneous coronary intervention) within the 4 weeks prior to enrollment, or planned within the next 4 weeks.

6. Severe valvular disease

7. Chronic and severe renal dysfunction defined as eGFR < 15 mL/min/1.73m2 based on local laboratory measurement done within 6 months prior to run-in***

8. History of liver cirrhosis

9. Active malignancy (excluding basal cell or treated squamous cell carcinoma of the skin) requiring treatment and with a life-expectancy of < 2 years.

10. Concurrent use of other experimental pharmacologic agents -

Related Conditions & MeSH terms

• Coronary Artery Disease
• Heart Diseases
• Heart Failure
• Myocardial Ischemia

Intervention

Drug:
• Colchicine 0.5 MG
Oral colchicine 0.5 mg daily
• Colchicine placebo
Placebo colchicine daily
• Thiamine Mononitrate 300 mg
Thiamine Mononitrate 300 mg daily

Locations

Country	Name	City	State
Canada	Hamilton Health Sciences Corporation	Hamilton	Ontario

Sponsors (3)

Lead Sponsor	Collaborator
Hamilton Health Sciences Corporation	Canadian Institutes of Health Research (CIHR), Population Health Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Colchicine arm: Time to first occurrence of a CV death, a HF event, MI, stroke, or arterial revascularization		3.5 years
Primary	Thiamine arm: Time to first occurrence of a CV death, or a HF event		3.5 years
Secondary	Time to death		3.5 years
Secondary	Time to first hospitalization		3.5 years